alexa Toxoplasmosis, Pancreatitis, Obesity and Drug Discovery
ISSN: 2165-7092

Pancreatic Disorders & Therapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Toxoplasmosis, Pancreatitis, Obesity and Drug Discovery

Helieh S. Oz*
University of Kentucky Medical Center, USA
Corresponding Author : Helieh S. Oz, DVM, PhD
AGAF, University of Kentucky Medical Center, USA
Tel: 859-277-0988
E-mail: [email protected]
Received Febuary 20, 2014; Accepted July 30, 2014; Published August 01, 2014
Citation: Helieh S. Oz (2014) Toxoplasmosis, Pancreatitis, Obesity and Drug Discovery . Pancreat Disord Ther 4:138. doi:10.4172/2165-7092.1000138
Copyright: © 2014 Oz HS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


 Toxoplasmosis, an infectious and inflammatory syndrome, is one of the most important foodborne diseases
causing hospitalization and death in U.S.A. Toxoplasma infects nucleated cells including pancreatic and destroys
the β cells. Toxoplasma is a Category B classified infection by CDC and NIH, which once infected the organisms
reside in tissues in cysts form for the host’s lifelong awaiting reactivation. Congenital toxoplasmosis occurs by
transplacental transmission during maternal infection or reactivation of organisms and manifests with spontaneous
abortion, or severe physical and mental defects. Currently, there is no safe and effective therapeutic modality
against congenital toxoplasmosis or the persistent chronic infection. Here, toxoplasmosis and possible involvement
of infection in induction of pancreatitis, and an experimental drug efficacy is discussed


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version